ARBAIZA, D.. Botulinum toxin type A for the treatment of tension-type headache. []. , 13, 5, pp.303-311. ISSN 1134-8046.

Objectives: To determine the time of onset of the analgesia, the < ficacy and the security of the application of the botulinu toxin A (BTA) in patient with tension-type headache (TH). Material and methods: Inclusion criteria: patients between 18 and 70 yeai diagnosis of TH according to the International Headache S ciety, two or more episodes of TH per month during at lea 3 months, non controlled TH with the standard treatmei normal neurological examination and signed inform consei Variables analyzed: Intensity of headache (IH), frequency presentation of headache (FH), duration of headache (DH sensibility to digit pressure (SDP) of the cranial musculatur number of painful points (NPD) of the cranial musculatur time of onset of the analgesia (TBA), time until the ma: mum effect of analgesia (TMA) and decrease of use of an.gesics (DUA). Evaluations in the days 0, 15 and 30. Fifty units of BT were applied to cranial musculature. The patients could continue with their previous analgesic therapy according to the evolution of the headache. Results: Twenty female patients were included with a median age of 47 years. IH 2.15 in the first evaluation diminished at 1.05 and 0.9 in the second and third evaluations (p=0.009 and 0.008). FH of 10.25 days diminished to 3.6 and 2.75 days (p=0.008 and 0.012). DH of 2.3 daily hours it diminished at 1.3 and 1.1 (p=0.009 in both). SDP 1.55 diminished at 0.5 and 0.55 (p=0.008 in both). NPD 2.65 diminished at 0.8 and 0.6 (p=0.010 and 0.006). TBA was 8 days and TMA was 25 days. DUA 5 diminished at 1.9 and 1.5. Around of 35% of the patients presented a probable adverse event of mild or moderate severity. Conclusion: TB-TO it is a simple, effective treatment and provides control of the TH. The technique is easy to reproduce. More studies are needed to value the number of applications and the total area of application, as probable factors in the analgesic response.

: Tension-type headache; botulinum toxin A; cranial musculature.

        · |     · |     · ( pdf )